Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status
Open accessThe DOI matches its Crossref record; 88 of the 91 references it cites were found in a registry or an index.
Abstract
Viloxazine has a long history of clinical use in Europe as an antidepressant, and has recently been repurposed into an extended-release form for the treatment of attention-deficit/hyperactivity disorder in the USA. An immediate-release formulation was approved for the treatment of depression in the UK in 1974, and was subsequently marketed there and in several European countries for 30 years with no major safety concerns. In contrast to first-generation antidepressants (e.g., tricyclic antidepressants, monoamine oxidase inhibitors), viloxazine was associated with a relatively low risk for cardiotoxicity. Gastrointestinal symptoms were the most commonly reported side effects. The therapeutic effects of viloxazine are thought to be primarily the result of its action as a norepinephrine reuptake inhibitor, although in vitro and preclinical in vivo animal data suggest that viloxazine may also impact the serotoninergic system. This review summarizes the evolving knowledge of viloxazine based on information from previously published preclinical and clinical investigations, and acquired unpublished historical study reports from both open-label and blinded controlled clinical trials. We review the chemical properties, mechanism of action, safety, and tolerability across these studies, and discuss the contemporary rationale for the development of this agent as an extended-release oral formulation for the treatment of attention-deficit/hyperactivity disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“has long been used in Europe to treat depression [74]”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Arzneimittelforschung: Eine Zukunftsoption für Ärzte?
Bethke, T. D. (2012) · Der Pneumologe · doi:10.1007/s10405-012-0601-3 · Cited by 3,261
The Neural Basis of Addiction: A Pathology of Motivation and Choice
Kalivas, P. W., & Volkow, N. D. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1403 · Cited by 2,757 · cited 1×
“The minimal impact of viloxazine on dopamine in the nucleus accumbens, a region known for its key role in substance use disorders [20, 21], may be associated with a low abuse liability [22].”
BackgroundFoye's Principles of Medicinal Chemistry
Foye, W. O., Lemke, T., & Williams, D. A. (2012) · Cited by 1,407
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830 · cited 1×
“In certain situations, stimulants can fail to provide satisfactory symptom control [79], and have a known potential for abuse [22].”
BackgroundFaraone, S. V. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.001 · Cited by 631 · cited 1×
“Notably, dysregulated dopamine signaling in the prefrontal cortex and amygdala has been implicated in the pathophysiology of ADHD [23–28], and is a primary target of many effective ADHD medications [27, 29, 30].”
BackgroundDopamine in Drug Abuse and Addiction: Results of Imaging Studies and Treatment Implications
Volkow, N. D., Fowler, J. S., Wang, G.-J., Swanson, J. M., & Telang, F. (2007) · Archives of Neurology · doi:10.1001/archneur.64.11.1575 · Cited by 605
Swanson, J. M., Kinsbourne, M., Nigg, J., Lanphear, B., Stefanatos, G. A., Volkow, N., Taylor, E., Casey, B. J., Castellanos, F. X., & Wadhwa, P. D. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9019-9 · Cited by 580
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.11.1652 · Cited by 528
Sharma, A., & Couture, J. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028013510699 · Cited by 516 · cited 1×
“Norepinephrine has long been implicated in ADHD pathophysiology [25, 63, 66], and serotonin has also been suggested to play a role in the hyperactivity/impulsivity deficits associated with ADHD [64, 65].”
BackgroundAttention-deficit/hyperactivity disorder (adhd) as a noradrenergic disorder
Biederman, J., & Spencer, T. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00192-4 · Cited by 513 · cited 1×
“Norepinephrine has long been implicated in ADHD pathophysiology [25, 63, 66], and serotonin has also been suggested to play a role in the hyperactivity/impulsivity deficits associated with ADHD [64, 65].”
BackgroundCatalá-López, F., Hutton, B., Núñez-Beltrán, A., Page, M. J., Ridao, M., Macías Saint-Gerons, D., Catalá, M. A., Tabarés-Seisdedos, R., & Moher, D. (2017) · PLOS ONE · doi:10.1371/journal.pone.0180355 · Cited by 396
Faraone, S. V., & Glatt, S. J. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04902pur · Cited by 387 · cited 1×
“However, nonstimulants, which are generally less effective and have a slower onset of effect than stimulants [84], are also not without limitations.”
BackgroundHeel, R. C., Morley, P. A., Brogden, R. N., Carmine, A. A., Speight, T. M., & Avery, G. S. (1982) · Drugs · doi:10.2165/00003495-198224030-00001 · Cited by 384
Fundamentals of Attention-Deficit/Hyperactivity Disorder: Circuits and Pathways
Arnsten, A. F. T. (2006) · The Primary Care Companion to The Journal of Clinical Psychiatry · Cited by 378
Pharmacologic Treatment of Attention Deficit–Hyperactivity Disorder
Cortese, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1917069 · Cited by 342
A Clinical Perspective of Attention-Deficit/Hyperactivity Disorder Into Adulthood
Wilens, T. E., & Dodson, W. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1003 · Cited by 274
CORKUM, P., MOLDOFSKY, H., HOGG-JOHNSON, S., HUMPHRIES, T., & TANNOCK, R. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199910000-00018 · Cited by 254
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder
Biederman, J., Spencer, T., & Wilens, T. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003973 · Cited by 253
The Dopamine Theory of Attention Deficit Hyperactivity Disorder (ADHD)
Levy, F. (1991) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048679109077746 · Cited by 234
ADHD and the Prefrontal Cortex
Arnsten, A. F. T. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.01.018 · Cited by 220
Impact of ADHD and its treatment on substance abuse in adults.
Wilens, T. E. (2004) · PubMed · Cited by 219
Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways.
Arnsten, A. F. T. (2006) · PubMed · Cited by 208
The Potential for Misuse and Abuse of Medications in ADHD: A Review
Clemow, D. B., & Walker, D. J. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.09.2801 · Cited by 198 · cited 2×
“In certain situations, stimulants can fail to provide satisfactory symptom control [79], and have a known potential for abuse [22].”
BackgroundThe neurobiological basis of ADHD
Curatolo, P., D'Agati, E., & Moavero, R. (2010) · Italian Journal of Pediatrics · doi:10.1186/1824-7288-36-79 · Cited by 189 · cited 1×
“Norepinephrine has long been implicated in ADHD pathophysiology [25, 63, 66], and serotonin has also been suggested to play a role in the hyperactivity/impulsivity deficits associated with ADHD [64, 65].”
BackgroundMeta-Analysis of Suicide-Related Behavior Events in Patients Treated With Atomoxetine
BANGS, M. E., TAUSCHER-WISNIEWSKI, S., POLZER, J., ZHANG, S., ACHARYA, N., DESAIAH, D., TRZEPACZ, P. T., & ALLEN, A. J. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31815d88b2 · Cited by 152 · cited 1×
“For example, they have been associated with minor changes in blood pressure or cardiovascular risk [85–87], precipitation of secondary mania [88, 89], and suicidal ideation [90], although these events are rare and generally restricted to vulnerable populations with pre-existing conditions.”
BackgroundMartínez-Raga, J., Knecht, C., Szerman, N., & Martínez, M. (2012) · CNS Drugs · doi:10.1007/s40263-012-0019-9 · Cited by 147
Does serotonin deficit mediate susceptibility to ADHD?
Banerjee, E., & Nandagopal, K. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.02.001 · Cited by 147 · cited 1×
“Norepinephrine has long been implicated in ADHD pathophysiology [25, 63, 66], and serotonin has also been suggested to play a role in the hyperactivity/impulsivity deficits associated with ADHD [64, 65].”
BackgroundKollins, S. H., Jain, R., Brams, M., Segal, S., Findling, R. L., Wigal, S. B., & Khayrallah, M. (2011) · Pediatrics · doi:10.1542/peds.2010-1260 · Cited by 125
Self-citationTreatment of depression--newer pharmacotherapies.
Mulrow, C. D., Williams, J. W., Trivedi, M. H., Chiquette, E., Aguilar, C., Cornell, J. E., Badgett, R. G., Noël, P. H., Lawrence, V. A., Lee, S., et al. (1999) · PubMed Central · Cited by 124
A Review of Pharmacological Management of Attention-Deficit/Hyperactivity Disorder
Briars, L., & Todd, T. (2016) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-21.3.192 · Cited by 117 · cited 1×
“, 3–12 h) duration of action [76] (although new formulations such as Mydayis® and Adhansia XR® have labeled efficacy up to 16 h [77, 78]), thus consistent treatment throughout the day can be difficult to achieve.”
BackgroundSoutullo, C. A., DelBello, M. P., Ochsner, J. E., McElroy, S. L., Taylor, S. A., Strakowski, S. M., & Keck, P. E. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00336-6 · Cited by 108
Yu, C., Garcia-Olivares, J., Candler, S., Schwabe, S., & Maletic, V. (2020) · Journal of Experimental Pharmacology · doi:10.2147/jep.s256586 · Cited by 96 · cited 6×
“A recent study found viloxazine to demonstrate weak competitive inhibition (< 25%) at histamine receptors H1 and H2 and muscarinic receptors M1–4, and notably low affinity towards monoamine oxidase A [15].”
BackgroundSelf-citationRole of the serotonin system in ADHD: treatment implications
Oades, R. D. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.10.1357 · Cited by 93
Pinder, R. M., Brogden, R. N., Speight, T. M., & Avery, G. S. (1977) · Drugs · doi:10.2165/00003495-197713060-00001 · Cited by 86 · cited 9×
“However, a separate account reported one overdose death following ingestion of an unknown amount of medication where the patient received no medical treatment [2].”
BackgroundMethodInfluentialNasser, A., Liranso, T., Adewole, T., Fry, N., Hull, J. T., Chowdhry, F., Busse, G. D., Cutler, A. J., Jones, N. J., Findling, R. L., et al. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.05.021 · Cited by 85
Self-citationTHE BINDING OF SOME ANTIDEPRESSANT DRUGS TO BRAIN MUSCARINIC ACETYLCHOLINE RECEPTORS
GOLDS, P. R., PRZYSLO, F. R., & STRANGE, P. G. (1980) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1980.tb14570.x · Cited by 76 · cited 1×
“It reduces the responsiveness of rat cortical neurons to acetylcholine [32, 33], shows negligible binding to the choline transporter, and essentially no impact on acetylcholine levels in the prefrontal cortex, nucleus accumbens, or amygdala [15, 34].”
Background2-(2-Ethoxyphenoxymethyl)tetra-hydro-1,4-oxazine Hydrochloride, a Potential Psychotropic Agent
Mallion, K. B., Todd, A. H., Turner, R. W., Bainbridge, J. G., Greenwood, D. T., Madinaveitia, J., Somerville, A. R., & Whittle, B. A. (1972) · Nature · doi:10.1038/238157a0 · Cited by 76 · cited 5×
“Data from the 1970s showed that viloxazine does not significantly inhibit the uptake of serotonin into human blood platelets [1] or CNS tissue [11, 12].”
BackgroundInfluentialThe Impact of Disasters and Their Aftermath on Mental Health: (Commentary)
Ursano, R. J., Cerise, F. P., DeMartino, R., Reissman, D. B., & Shear, M. K. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0102 · Cited by 75
Hutson, P. H., Pennick, M., & Secker, R. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.02.014 · Cited by 72 · cited 1×
“Notably, dysregulated dopamine signaling in the prefrontal cortex and amygdala has been implicated in the pathophysiology of ADHD [23–28], and is a primary target of many effective ADHD medications [27, 29, 30].”
BackgroundViggiano, D., Ruocco, L. A., Arcieri, S., & Sadile, A. G. (2004) · Neural Plasticity · doi:10.1155/np.2004.133 · Cited by 71
Johnson, J. K., Liranso, T., Saylor, K., Tulloch, G., Adewole, T., Schwabe, S., Nasser, A., Findling, R. L., & Newcorn, J. H. (2020) · Journal of Attention Disorders · doi:10.1177/1087054719836159 · Cited by 62 · cited 1×
“In a recent phase II trial in children aged 6–12 years with ADHD (n = 222), treatment-emergent AEs (TEAEs) were generally mild or moderate, with only three severe TEAEs reported (tearfulness, irritability, and decreased appetite) [68].”
BackgroundSelf-citationEffects of antidepressant drugs on histamine-H1 receptors in the brain
Hall, H., & Ögren, S. O. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90494-6 · Cited by 61 · cited 1×
“, tricyclic antidepressants [TCAs] and monoamine oxidase inhibitors), viloxazine demonstrates negligible activity in the cholinergic system [12, 13], and lacks any appreciable activity towards histamine [13, 31].”
BackgroundTreuer, T., Gau, S. S.-F., Méndez, L., Montgomery, W., Monk, J. A., Altin, M., Wu, S., Lin, C. C. H., & Dueñas, H. J. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0093 · Cited by 58
Pharmacological and therapeutic directions in ADHD: Specificity in the PFC
Levy, F. (2008) · Behavioral and Brain Functions · doi:10.1186/1744-9081-4-12 · Cited by 56
Nasser, A., Liranso, T., Adewole, T., Fry, N., Hull, J. T., Chowdhry, F., Busse, G. D., Melyan, Z., Cutler, A. J., Findling, R. L., et al. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.01.027 · Cited by 55 · cited 1×
“In four subsequent phase III trials in children aged 6–11 years [36, 37] and adolescents aged 12–17 years [38, 39], viloxazine ER was well-tolerated over 6–8 weeks of treatment (pooled N = 1117).”
BackgroundSelf-citationCombination pharmacotherapy for adult ADHD
Adler, L. A., Reingold, L. S., Morrill, M. I., & Wilens, T. E. (2006) · Current Psychiatry Reports · doi:10.1007/s11920-006-0044-9 · Cited by 52
The Disposition and Metabolism of I.C.I. 58,834 (Viloxazine) in Humans
Case, D. E., & Reeves, P. R. (1975) · Xenobiotica · doi:10.3109/00498257509056097 · Cited by 52
Acute effects of atypical antidepressants on various receptors in the rat brain.
Hall, H., Sällemark, M., & Wedel, I. (2009) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1984.tb01945.x · Cited by 51 · cited 1×
“Other in vitro studies found no effect on dopamine release in striatal tissue [14], and little affinity for, or potency at, either dopamine receptors or the transporter [11, 14, 15, 19].”
BackgroundNasser, A. F., Liranso, T., Adewole, T., Fry, N., Hull, J. T., Busse, G. D., Chowdhry, F. A., Cutler, A. J., Jones, N. J., Findling, R. L., et al. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001404 · Cited by 49 · cited 1×
“In four subsequent phase III trials in children aged 6–11 years [36, 37] and adolescents aged 12–17 years [38, 39], viloxazine ER was well-tolerated over 6–8 weeks of treatment (pooled N = 1117).”
BackgroundSelf-citationAggression, Mania, and Hypomania Induction Associated With Atomoxetine
Henderson, T. A., & Hartman, K. (2004) · Pediatrics · doi:10.1542/peds.2004-1140 · Cited by 48 · cited 1×
“For example, they have been associated with minor changes in blood pressure or cardiovascular risk [85–87], precipitation of secondary mania [88, 89], and suicidal ideation [90], although these events are rare and generally restricted to vulnerable populations with pre-existing conditions.”
BackgroundLippmann, W., & Pugsley, T. A. (1976) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y76-069 · Cited by 45 · cited 6×
“Data from the 1970s showed that viloxazine does not significantly inhibit the uptake of serotonin into human blood platelets [1] or CNS tissue [11, 12].”
BackgroundInfluentialNasser, A. F., Liranso, T., Adewole, T., Fry, N., Hull, J. T., Chowdhry, F. A., Busse, G. D., Melyan, Z., Cutler, A. J., Findling, R. L., et al. (2021) · PubMed · Cited by 44
Self-citationBlackburn, T. P., Foster, G. A., Greenwood, D. T., & Howe, R. (1978) · European Journal of Pharmacology · doi:10.1016/0014-2999(78)90291-1 · Cited by 42 · cited 4×
“Other in vitro studies found no effect on dopamine release in striatal tissue [14], and little affinity for, or potency at, either dopamine receptors or the transporter [11, 14, 15, 19].”
BackgroundInfluentialGuanfacine and secondary mania in children
Horrigan, J. P., & Barnhill, L. J. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00183-9 · Cited by 41 · cited 1×
“For example, they have been associated with minor changes in blood pressure or cardiovascular risk [85–87], precipitation of secondary mania [88, 89], and suicidal ideation [90], although these events are rare and generally restricted to vulnerable populations with pre-existing conditions.”
BackgroundBayliss, P. F. C., & Duncan, S. (1974) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1974.tb00282.x · Cited by 40 · cited 1×
“Minimal anticholinergic effects were found in human double-blind randomized studies of viloxazine 100 mg vs imipramine 50 mg [55, 56], though both drugs induced transient tachycardia 4 h post-dose [55].”
BackgroundCarbamazepine-viloxazine interaction in patients with epilepsy.
Pisani, F., Fazio, A., Oteri, G., Perucca, E., Russo, M., Trio, R., Pisani, B., & Perri, R. D. (1986) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.49.10.1142 · Cited by 38 · cited 2×
“Clinical studies using viloxazine IR with or without concomitant anticonvulsant therapy described the drug to be non-epileptogenic or, at least, less epileptogenic than contemporaneous antidepressants; as a result, it was also studied as a possible treatment for depressed patients with epilepsy [42, 58, 59].”
BackgroundMeldrum, B. S., Anlezark, G., Adam, H. K., & Greenwood, D. T. (1982) · Psychopharmacology · doi:10.1007/bf00432547 · Cited by 37
Alcoholism and depression: a placebo controlled study with viloxazine.
Altamura, A. C., Mauri, M. C., Girardi, T., & Panetta, B. (1990) · PubMed · Cited by 35
Müller-Oerlinghausen, B. (1999) · PubMed · Cited by 30
Sayer, G. R., McGough, J. J., Levitt, J., Cowen, J., Sturm, A., Castelo, E., & McCracken, J. T. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0264 · Cited by 28
The Disposition and Metabolism of LCI. 58,834 (ViloxazJne) in Animals
Case, D. E., Illston, H., Reeves, P. R., Shuker, B., & Simons, P. (1975) · Xenobiotica · doi:10.3109/00498257509056096 · Cited by 27
Does viloxazine have epileptogenic properties?
Edwards, J. G., & Glen‐Bott, M. (1984) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.47.9.960 · Cited by 27 · cited 2×
“Viloxazine was ultimately not contraindicated for depressed patients with epilepsy [46, 58].”
BackgroundCathala, A., Devroye, C., Drutel, G., Revest, J., Artigas, F., & Spampinato, U. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.09.015 · Cited by 27 · cited 1×
“Importantly, this action on serotonin receptors may play a role in serotonin release: antagonism of 5-HT2B receptors located on GABAergic interneurons has been shown to disinhibit tonic inhibitory control of serotonin neurons innervating the medial prefrontal cortex, indirectly stimulating serotonin release in this re…”
BackgroundAmphetamines, Atomoxetine and the Risk of Serious Cardiovascular Events in Adults
Schelleman, H., Bilker, W. B., Kimmel, S. E., Daniel, G. W., Newcomb, C. W., Guevara, J. P., Cziraky, M. J., Strom, B. L., & Hennessy, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0052991 · Cited by 26
Viloxazine, sleep, and subjective feelings
Březinová, V., Adam, K., Chapman, K., Oswald, I., & Thomson, J. A. (1977) · Psychopharmacology · doi:10.1007/bf01457846 · Cited by 24 · cited 1×
“, broken and reduced sleep, decreased rapid eye movement sleep) [61] and at 100 mg/day depressed the critical flicker frequency (a test of general CNS stimulation or depression), though this effect was not seen at lower doses [56].”
BackgroundBlood level studies with viloxazine hydrochloride in man.
Bayliss, P. F. C., & Case, D. (1975) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1975.tb01577.x · Cited by 24 · cited 2×
“5 hours after being well absorbed through the small intestine [41].”
BackgroundMartin, I. L., Baker, G. B., & Mitchell, P. R. (1978) · Neuropharmacology · doi:10.1016/0028-3908(78)90018-7 · Cited by 22 · cited 3×
“Other in vitro studies found no effect on dopamine release in striatal tissue [14], and little affinity for, or potency at, either dopamine receptors or the transporter [11, 14, 15, 19].”
BackgroundBayliss, P. F. C., Dewsbury, A. R., Donald, J. F., Harcup, J. W., Mayer, M., Million, R., Molla, A. L., Murphy, J. E., Plant, B., & Shaoul, E. (1974) · Journal of International Medical Research · doi:10.1177/030006057400200402 · Cited by 21 · cited 4×
“In two separate studies of patients with mild-to-moderate depression, 150–200 mg/day of viloxazine was found to be efficacious in reducing symptoms of depression and anxiety, with mild side effects that were primarily gastrointestinal in nature [47, 48].”
BackgroundInfluentialCitalopram and Viloxazine in the treatment of depression by means of slow drop infusion
Bouchard, J. M., Strub, N., & Nil, R. (1997) · Journal of Affective Disorders · doi:10.1016/s0165-0327(97)00078-5 · Cited by 20
Evaluation of the Effect of SPN-812 (Viloxazine Extended-Release) on QTc Interval in Healthy Adults
Nasser, A. F., Faison, S. L., Liranso, T., Adewole, T., Busse, G. D., Fava, M., Kleiman, R., & Schwabe, S. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20m13395 · Cited by 20 · cited 1×
“In a contemporary study using supratherapeutic doses of viloxazine ER (1800 mg) in healthy adults, there was no effect on cardiac repolarization or other electrocardiogram parameters [54].”
BackgroundSelf-citationSOME PRELIMINARY OBSERVATIONS ON ICI 58 834, A NEW PSYCHOTROPIC AGENT, IN MAN
Kirby, M. J., & TURNER, P. (1974) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1974.tb00227.x · Cited by 19 · cited 1×
“Double-blind, placebo-controlled crossover studies of low doses (20–80 mg) in healthy volunteers indicated no significant differences between viloxazine and placebo on assessments of reaction time, coordination, or cognitive task performance [47, 62].”
BackgroundPisani, F., Fazio, A., Spina, E., Artesi, C. J., Pisani, B., Russo, M., Trio, R., & Perucca, E. (1986) · Psychopharmacology · doi:10.1007/bf00179180 · Cited by 18 · cited 3×
“Clinical studies using viloxazine IR with or without concomitant anticonvulsant therapy described the drug to be non-epileptogenic or, at least, less epileptogenic than contemporaneous antidepressants; as a result, it was also studied as a possible treatment for depressed patients with epilepsy [42, 58, 59].”
BackgroundPOTENTIATION OF RESPONSES TO MONOAMINES BY ANTIDEPRESSANTS AFTER DESTRUCTION OF MONOAMINE AFFERENTS
Jones, R. S. G., & Roberts, M. H. T. (1979) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1979.tb07858.x · Cited by 18 · cited 1×
“Viloxazine increased neuronal sensitivity to serotonin [16, 17], and potentiated both the 5-hydroxytryptophan (precursor to serotonin)-induced behavioral syndrome in mice and the 5-hydroxytryptophan-induced hind-limb extensor reflex in rats, thought to reflect increased activation of serotonin receptors [12].”
BackgroundViloxazine: a Review of the Literature
Ban, T. A., McEvoy, J. P., & Wilson, W. H. (2017) · International Pharmacopsychiatry · doi:10.1159/000468422 · Cited by 17 · cited 4×
“During its period of commercial use in Europe beginning in the 1970s, the safety profile of viloxazine was well established [2, 46].”
BackgroundInfluentialMOIZESZOWICZ, J., & SUBIRÁ, S. (1977) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1977.tb04589.x · Cited by 16 · cited 2×
“A single-blind trial comparing 4 weeks of nomifensin vs viloxazine (150 mg/day) administration in elderly depressed patients again showed significant improvements on the Hamilton Rating Scale for depression with both treatments [51].”
BackgroundMethodJones, R. S. G. (1980) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y80-087 · Cited by 16 · cited 1×
“It reduces the responsiveness of rat cortical neurons to acetylcholine [32, 33], shows negligible binding to the choline transporter, and essentially no impact on acetylcholine levels in the prefrontal cortex, nucleus accumbens, or amygdala [15, 34].”
BackgroundCases of Overdosage with Viloxazine Hydrochloride (Vivalan†)
Brosnan, R. D., Busby, A. M., & Holland, R. P. C. (1976) · Journal of International Medical Research · doi:10.1177/030006057600400201 · Cited by 15 · cited 5×
“There are relatively few documented suicide attempts by humans taking viloxazine [2, 52].”
BackgroundInfluentialCombination Therapy Patterns and Predictors of ADHD in Commercially Insured and Medicaid Populations
Molife, C., Bernauer, M. J., Farr, A. M., Haynes, V. S., & Kelsey, D. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.09.2586 · Cited by 12
Inhibition of monoamine oxidase by viloxazine in rats
Martínez, C., Dominiak, P., Kees, F., & Grobecker, H. (1986) · PubMed · doi:10.5283/epub.26849 · Cited by 9
Viloxazine and neurotransmitter function.
Greenwood, D. T. (1982) · PubMed · Cited by 9
Bayliss, P. F. C., Harcup, J. W., Mayer, M., Million, R., Murphy, J. E., Plant, B., & Shaoul, E. (1974) · Journal of International Medical Research · doi:10.1177/030006057400200401 · Cited by 8 · cited 2×
“In two separate studies of patients with mild-to-moderate depression, 150–200 mg/day of viloxazine was found to be efficacious in reducing symptoms of depression and anxiety, with mild side effects that were primarily gastrointestinal in nature [47, 48].”
BackgroundModification of cortical neuron responses to acetylcholine by viloxazine
Jones, R. S. G., & Roberts, M. H. T. (1979) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1979.tb13438.x · Cited by 7 · cited 1×
“It reduces the responsiveness of rat cortical neurons to acetylcholine [32, 33], shows negligible binding to the choline transporter, and essentially no impact on acetylcholine levels in the prefrontal cortex, nucleus accumbens, or amygdala [15, 34].”
BackgroundViloxazine in depressed women: clinical response and cardiovascular effects.
Corona, G. L., Frattini, P., Ml, C., Santagostino, G., Schinelli, S., Zerbi, F., Cairoli, S., Tosca, P., & Savoldi, F. (1987) · PubMed · Cited by 6
[Studies on a novel antidepressant (viloxazin) by means of time-series analysis of TV data].
Renfordt, E., Busch, H. M., Fähndrich, E., & Müller-Oerlinghausen, B. (1976) · PubMed · Cited by 6
Multicentre Study with Viloxazine (Vivalan®) in Depressed Patients
Kabeš, J., Dostal, T., Náhunek, K., Švestka, J., Molčan, J., Caplová, T., Hynek, K., Faltus, F., & Holland, R. P. C. (2017) · International Pharmacopsychiatry · doi:10.1159/000468442 · Cited by 6 · cited 5×
“While commercially available, viloxazine was used in both adult and elderly patients as a two-times or three-times daily treatment [2], and was distributed under the trade names Viloxazin [3], Emovit [4], Viloxazina [5], Viloxazinum [5], Vivarint [6], Vicilan [2], and Vivalan [7].”
BackgroundMethodInfluentialJones, R. S. G., & Roberts, M. H. T. (1978) · PubMed · Cited by 2
Research works printed but not linked: 6
- Marsh W Enna SJ Bylund DB Viloxazine xPharm: the comprehensive pharmacology reference 2007 Amsterdam Elsevier Inc
- National Center for Biotechnology Information, PubChem database. Viloxazine, CID = 5666. https://pubchem.ncbi.nlm.nih.gov/compound/Viloxazine. Accessed 17 Jan 2019.
- Murphy JE Vivalan: drug profile J Int Med Res 1975 3 122 125
- Greenwood DT Animal pharmacology of viloxazine (Vivalan) J Int Med Res. 1975 3 18 28
- Turner P Bayliss PFC Ghose K Clinical pharmacoolgy of viloxazine (Vivalan) J Int Med Res. 1975 3 41 47
- Murphy JE Vivalan: drug profile J Int Med Res. 1975 3 112 115
Cited by
Chirality of New Drug Approvals (2013–2022): Trends and Perspectives
McVicker, R. U., & O’Boyle, N. M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02239 · Cited by 255
Becker, S. P., Willcutt, E. G., Leopold, D. R., Fredrick, J. W., Smith, Z. R., Jacobson, L. A., Burns, G. L., Mayes, S. D., Waschbusch, D. A., Froehlich, T. E., et al. (2023) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2022.07.821 · Cited by 175
Nazarova, V. A., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1066988 · Cited by 111
Functional Impairments Associated With ADHD in Adulthood and the Impact of Pharmacological Treatment
Kosheleff, A. R., Mason, O., Jain, R., Koch, J., & Rubin, J. S. (2023) · Journal of Attention Disorders · doi:10.1177/10870547231158572 · Cited by 136
“Although the abuse liability of viloxazine extended-release has not been directly tested in humans, the original formulation of viloxazine has a 30+ year history of clinical use in Europe, with no indication of abuse potential (Findling et al., 2021).”
BackgroundDrug Repurposing of Generic Drugs: Challenges and the Potential Role for Government
van der Pol, K. H., Aljofan, M., Blin, O., Cornel, J. H., Rongen, G. A. P. J. M., Woestelandt, A.-G. B., & Spedding, M. (2023) · Applied Health Economics and Health Policy · doi:10.1007/s40258-023-00816-6 · Cited by 68
“An example of a successfully repurposed generic drug is viloxazine, a selective noradrenaline uptake inhibitor, which was originally approved and marketed for the treatment of depression in Europe but was never approved or marketed in the USA [41].”
Background
Metadata
- Authors
- Findling, R. L., Candler, S. A., Nasser, A. F., Schwabe, S., Yu, C., Garcia-Olivares, J., O’Neal, W., & Newcorn, J. H.
- Affiliations
- Virginia Commonwealth University (US)
- Supernus Pharmaceuticals (United States) (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Findling, Robert L.
- ORCID
- Venue
- CNS Drugs
- Published
- 2021-05-18
- Volume
- 35
- Issue
- 6
- Pages
- 643-653
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC8219567
- OpenAlex
- W3160925470
- Cited by
- 55
- References
- 91
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 12 · 2023: 11 · 2022: 16 · 2021: 2
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- CNS Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Sunovion
- Supernus Pharmaceuticals
- National Institute of Child Health and Human Development
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- viloxazine, antidepressants, attention deficit hyperactivity disorder, drug repurposing, sustained-release formulation, norepinephrine reuptake inhibitors, serotonergic system, cardiotoxicity, gastrointestinal adverse effects, drug safety and tolerability, mechanism of action
- MeSH terms
- Administration, Oral, Animals, Attention Deficit Disorder with Hyperactivity, Central Nervous System Diseases, Delayed-Action Preparations, Humans, Viloxazine, Adrenergic Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
